TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02446119

Intervention type: DEVICE
Intervention: EndoFLIP
Description: Measurement of pyloric resistance and compliance

Intervention type: DEVICE
Intervention: EndoFLIP
Description: Measurement of pyloric resistance and compliance
Study: NCT04670367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk 30mins
Description: aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk plus Baduanjin
Description: Walk 30mins then Baduanjin 12mins per day, 5 times per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: routine care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin
Description: Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
Study: NCT00663182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5 mg/d
Study: NCT01421719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystoscopic injection of Botox into the urinary bladder
Description: 100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
Study: NCT00999778

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver-Mediated Intervention
Description: 1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver-Education Intervention
Description: The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
Study: NCT04405453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trapezius muscle injection
Description: TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trapezius muscle injection
Description: TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive
Study: NCT01773759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention child care programs
Description: Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
Study: NCT03823313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCAI (Spiritual Care Assessment and Intervention)
Description: 4 sessions completed with an IU Health chaplain using a framework of questions called the Spiritual Care Assessment And Intervention tool. The weekly sessions will focus on one of the 4 areas of spiritual experience (meaning and purpose, relationships, transcendence and peace, self-worth and identity)
Study: NCT02981615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
Study: NCT02692638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early laparoscopic enterolysis
Description: The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nonoperative management
Description: Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
Study: NCT03227640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stripping technique
Description: The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser (AcuPulse Duo, Lumenis)
Description: The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
Study: NCT01898260

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrafilcon B contact lens
Description: Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrafilcon B contact lens
Description: Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lens
Description: Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lens
Description: Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
Study: NCT03323281

Intervention type: OTHER
Intervention: Neuropsychological assessments
Description: Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)

Intervention type: OTHER
Intervention: Neuropsychological assessments
Description: Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
Study: NCT02871752

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion
Description: mindfulness-based stress reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion
Description: mindfulness-based stress reduction
Study: NCT03124342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VANDERBILT ICU RECOVERY PROGRAM
Description: 10-component ICU Recovery Program intervention, including:~1. Nurse Practitioner In-Person Visit at the time of transfer from the ICU~2. Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~3. Performance of formal medication reconciliation at the time of transfer from the ICU~4. Access to a dedicated 24-hour a day, 7-day a week contact line~5. ICU Recovery Clinic Visit Medical Examination.~6. ICU Recovery Clinic Medication Reconciliation and Counseling~7. ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~8. ICU Recovery Clinic Case Management. A brief case management consultation~9. ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~10. Directed Subspecialty Referrals
Study: NCT00785642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
Study: NCT00156676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Study: NCT01171482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 15mg/kg/day continuous IV from day 1 to day 6 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: 4mg/day IV push from day 1 to day 4 every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: 400 mg BID every 28 days
Study: NCT01069900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/Clavulanate
Description: Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem placebo
Description: Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate placebo
Description: Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
Study: NCT00713167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (Vitagrape)
Description: Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Grape Seed Extract
Description: Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months
Study: NCT01429740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution or capsules
Study: NCT00865410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrika Bupropion 150 mg Extended-Released Tablet
Description: A: Experimental Subjects received Abrika formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Study: NCT02386644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAMG-1 Immunoassay
Description: Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound transperineal assessment
Description: Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound amniotic fluid index measurement
Description: Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speculum examination
Description: Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrazine test
Description: To assess acid , alkaline status of pooled fluid in vagina.
Study: NCT01888302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT02606201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peri sphincter injection Autologous myofibers
Description: The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control.
Study: NCT01227018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiologic imaging
Description: radiologic modalities used to evaluate response to treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood draw
Description: Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
Study: NCT01851759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinepazide
Description: 2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
Study: NCT01424215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
Study: NCT02904954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durvalumab plus SBRT
Description: Intravenously plus radiotherapy
Study: NCT01417377

Intervention type: DRUG
Intervention: Mircera
Description: Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
Study: NCT01621802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: One dose administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: One dose administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: One dose administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: One dose administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: One dose administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: One dose administered subcutaneously in the triceps region of the right arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Kinrix
Description: One dose administered by deep intramuscular injection in the upper left deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kinrix
Description: One dose administered by deep intramuscular injection in the upper left deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad
Description: One dose administered subcutaneously in the triceps region of the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad
Description: One dose administered subcutaneously in the triceps region of the left arm.
Study: NCT02948634

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Phoenix Laser Treatment
Description: Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Phoenix Laser Treatment
Description: The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
Study: NCT02405377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hydration
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hydration
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride ﬂuid administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride ﬂuid administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-French catheter
Study: NCT00433043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker (carvedilol or metoprolol succinate)
Description: Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker (carvedilol or metoprolol succinate)
Description: Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT (cardiac resynchronization therapy)
Description: Both arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT (cardiac resynchronization therapy)
Description: Both arms